Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Biotechnology

Healthcare
$7.48 -0.89%

-$0.04 today

Market cap
$3.46B
Beta
0.70
P/E (TTM)
-4.6
EPS (TTM)
-$0.85
52W Low $1.66High $5.63

Volume 6.99M

Average 14.09M

IOVA Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Iovance Biotherapeutics, Inc.NASDAQ: IOVA

Operating Income · Q3 FY2026 · quarter ended Sep 2026

Operating income remains negative

Q3 FY2026 operating income was -$23.97M, compared with -$89.76M a year earlier. Trailing-twelve-month operating income was -$230.38M.

Context

  • Operating income amounted to 151.1% of revenue in FY2025, down 89.8 pp from a year earlier.
  • Operating income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether operating income reaches the consensus estimate from 5 analysts of -$169.06M (+57.5%) for the fiscal year ending Dec 2026, a step up from the -0.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$23.97M+53.8% QoQ
Last fiscal yearDec 2025
-$398.21M-0.7% YoY
LTMSep 2026
-$230.38M+44.0% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+73.3%+72.7%-0.6 pp
1 year-0.7%+57.5%+58.3 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(398.21M) USD
Year-over-year change
-0.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How IOVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +44.0% is the 2nd highest of 10, against a peer median of +29.7%.
  • Operating income amounts to 60.8% of revenue for IOVA, versus a peer median of 71.8%.
IOVA Competitors
Operating Income for IOVA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GMABGenmab A/SLTM Jun 2026$1.33B USD—-41.6%32.3%
LEGNLegend Biotech CorporationLTM Sep 2026$34.1M USD+117.9%—2.5%
IMCRImmunocore Holdings plcLTM Mar 2026-$29.36M USD+38.3%—7.6%
STTKShattuck Labs, Inc.LTM Mar 2026-$52.66M USD+29.7%—5266.4%
ALXOALX Oncology Holdings Inc.LTM Mar 2026-$91.17M USD+33.2%——
FATEFate Therapeutics, Inc.LTM Mar 2026-$139.42M USD+30.5%—2207.5%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026-$230.38M USD+44.0%—60.8%
IBRXImmunityBio, Inc.LTM Sep 2026-$274.16M USD-5.1%—150.2%
IMNMImmunome, Inc.LTM Sep 2026-$300.69M USD-28.4%——
REPLReplimune Group, Inc.LTM Dec 2025-$326.46M USD-35.4%——
BNTXBioNTech SELTM Jun 2026-€1.9B EUR-116.6%—71.8%
Peer median (excluding IOVA) —+29.7%-41.6%71.8%

Competitors are the stored peer set for IOVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue001.19M164.07M263.5M
Cost of Revenue0010.76M124M173.18M
Gross Profit00(9.57M)40.08M90.32M
Gross Margin——-804.5%24.4%34.3%
Research & Development259.04M294.78M344.08M282.34M300.27M
Selling, General & Admin83.66M104.1M106.92M153.02M152.32M
Operating Expenses342.7M398.88M450.99M435.35M488.53M
Depreciation & Amortization13.98M21.14M33.13M43.61M47.32M
EBITDA(328.27M)(371.77M)(414.39M)(331.4M)(350.89M)
EBITDA Margin——-34851.9%-202.0%-133.2%
Operating Income(342.7M)(398.88M)(460.56M)(395.28M)(398.21M)
Operating Margin——-38735.0%-240.9%-151.1%
Interest Income451K2.99M13.04M20.27M10.31M
Interest Expense02.99M000
Other Income / Expenses451K2.99M13.04M20.27M5.16M
Income Before Tax(342.25M)(395.89M)(447.52M)(375.01M)(393.05M)
Pre-Tax Margin——-37638.0%-228.6%-149.2%
Income Tax Expense00(3.48M)(2.83M)(2.07M)
Net Income(342.25M)(395.89M)(444.04M)(372.18M)(390.98M)
Net Margin——-37345.4%-226.8%-148.4%
EPS (Basic)(2.23)(2.49)(1.89)(1.28)(1.09)
EPS (Diluted)(2.23)(2.49)(1.89)(1.28)(1.09)
Weighted Avg Shares153.41M159.26M235.13M289.88M357.35M
Weighted Avg Shares (Diluted)153.41M159.26M235.13M289.88M357.35M

Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Intrinsic Alpha fair value

Locked

Current Price

$7.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.